No significant cognitive impairment operationalized as either an intelligence quotient (IQ) < for children with SJMB baseline testing or based on clinician judgment in the case of missing baseline IQ Significant cognitive impairment or documented psychologic impairment Conditions that may increase the risk of the diet or significantly reduce compliance (i.e. cognitive impairment, frank dementia, etc) Performance status >= % (Karnofsky); patients > years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist; Prior cognitive-behavioral therapy Performance status >=% (Karnofsky); patients > years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist Baseline Montreal Cognitive Assessment (MOCA) score of or lower Cognitive or mental health impairment that inhibits group treatment Cognitive impairment that precludes a patient from acting as his or her own agent to provide informed consent Considered by the investigator to be an unsuitable or unstable candidate (e.g., due to cognitive impairment) Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc). Cognitive impairment such as to preclude informed consent Baseline Montreal Cognitive Assessment (MOCA) score of or lower Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.) Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc). Cognitive impairment Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.). Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc). In the opinion of the treating investigator, patients must have adequate cognitive abilities to complete the neurocognitive components of the study. Patient with cognitive impairment Baseline Montreal Cognitive Assessment (MOCA) score of or lower. Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.). Absence of any serious cognitive or psychiatric problems potentially hampering compliance with the study and follow-up schedule Cognitive impairment sufficient to render the patient incapable of giving informed consent Patients with cognitive impairment or likely to develop cognitive impairment while on study Patients must have the cognitive ability to participate in the study Global cognitive impairment based on education-adjusted scores (details below) on the Telephone Interview for Cognitive Status-modified The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia) Prior history of neurologic or psychiatric disease believed to impact cognitive function Patients scoring >= on the Blessed Orientation-Memory-Concentration Test (BOMC) (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Overt cognitive difficulty demonstrated by not being clearly oriented to person or place or time Significant cognitive impairment or documented psychologic impairment Severe cognitive or hearing impairment that is documented in the medical record (one that would make it difficult to comprehend and remember the material covered during study phone sessions) Unable to provide meaningful consent (e.g., severe cognitive impairment) Presence of cognitive impairment disorder (i.e. delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection, as detected during the ICCAN intake process In the judgment of the consenting professional, clinician or principal investigator (PI) and/or as per medical record, severe psychopathology or cognitive impairment likely to interfere with the participation or completion of the protocol or ability to provide meaningful information. Women with cognitive impairment that precludes informed consent and those unable to provide consent in English Cognitive or psychiatric conditions prohibiting study consent or participation If visual, hearing, or cognitive impairment will interfere with intervention Patients must have subjective complaints of cognitive deficits No history of cognitive disorder Are of limited decision making capacity, including those who score or less on the Montreal Cognitive Assessment (MoCA) assessment Patient makes or more errors on a validated -item cognitive screener or exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation FCG exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation Patients with cognitive deficits Significant cognitive impairment Significant cognitive impairment as determined by either an intelligence quotient (IQ) of =< or by clinician judgment Major sensory or motor impairment that would preclude valid cognitive testing Inability of the patient to provide informed consent (i.e. dementia, cognitive impairment, non-English speakers) Medical or other issue prohibiting computer use, reading or ability to comply with all study procedures or unable to communicate via phone (e.g., significant vision, hearing or cognitive impairment, major illness, hospitalization) The child has a significant cognitive impairment that might hinder participation (determination made in consultation with attending physician, oncologist, and parents) Do not have cognitive or visual impairments that would preclude use of the app Cognitive or hearing impairment Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes prohibits informed consent or participation in the study Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes prohibits informed consent or participation in the study Severe cognitive dysfunction impairing ability to provide informed consent or consume study drug Cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist PHASE : PARENT EXCLUSION CRITERIA: Patient has physician- or caregiver-reported cognitive delay or impairment that would prevent self-management of healthcare Known medical history of significant psychiatric or cognitive impairment DCG: Cognitive impairment Cognitive impairment And/or in the rare instance of the presence of a comorbidity that does not fall into any of the above mentioned exclusion criteria, but that is clinically determined to significantly interfere with the patients ability to participate in the study (e.g., cognitive impairment) Has been diagnosed with psychotic, addictive, and major cognitive disorders Patients with significant cognitive impairment or documented psychologic impairment Doctor of medicine (MD) confirmed cognitive impairment Cognitive impairment documented in the medical record Unable to provide meaningful consent (e.g., women with severe cognitive impairment such that the descriptions of the research are not clearly understood will be excluded) Medical record documentation of cognitive impairment that would preclude the ability to provide informed consent Can provide informed consent (e.g., no cognitive impairment) SUBJECT: Significant cognitive, behavioral, or emotional impairments as judged by an investigator that would prevent the child from understanding or completing the intervention or assessment measures. Moderate or worse cognitive impairment as indicated by a score of or less on the Callahan six-item cognitive screening tool Clear cognitive sequelae from the head injury and cognitive rehabilitation following the injury In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in Geriatric Specific Psychoeducational Intervention; the Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool; patients must have a BOMC score less than or equal to Cognitive or psychiatric disorder that would interfere with ability to provide informed consent or answer survey questions reliably\r\n* Any of these Diagnostic and Statistical Manual- (DSM-) cognitive and psychiatric disorders would make someone ineligible: bipolar; delusional; dissociative; intellectual developmental; neurocognitive; psychotic; schizophreniform, schizophrenia, and schizoaffective Patients with opioid induced neurotoxicity (OIN) as the primary reason for OR as they may manifest symptoms of cognitive impairment Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach. Patients with cognitive dysfunction PHASE I AIM : Clinical evidence of cognitive or psychological impairment PHASE I AIM .: Clinical evidence of cognitive or psychological impairment PHASE I AIM .: Clinical evidence of cognitive or psychological impairment PHASE II AIM : Clinical evidence of cognitive or psychological impairment Existing history of severe cognitive impairment in the child as reported by the parents or documented in the child's City of Hope medical records Diagnosed cognitive impairment Severe cognitive impairment Previously identified cognitive impairment, which in the judgment of the principal or associate investigators would compromise the donors ability to understand the educational materials or the board game rules and procedures, and is likely to interfere with the study procedures or results Cognitive impairment (part II only) Severe cognitive, visual, or hearing impairment that would preclude DA viewing Cognitive impairment or mental illness that would impair ability to provide consent or participate in the program Patients with known cognitive impairments FACT-Cog score less than on the Perceived Cognitive Impairment subscale Subjective complaint of cognitive concerns at time of enrollment Patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction. Hearing level and cognitive ability to follow test directions Neurological or cognitive impairment Able to undergo informed consent procedures and hours of testing, plus -hour cognitive rehabilitation sessions with breaks Currently on stimulants or other medications intended to treat cognitive impairment Report cognitive impairment since starting chemotherapy as assessed by four questions from the Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog) Major psychiatric illness or cognitive impairment that in the judgment of the investigator would preclude study participation Patient makes or more errors on a validated -item cognitive screener or exhibits significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation Caregiver exhibits significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent Regularly used cognitive behavioral therapy in the last weeks for sleep disturbance Regularly used cognitive behavioral therapy in the last weeks Cognitive impairment (>= on the Short Portable Mental Status Questionnaire [SPMSQ]) Intact cognitive status Do not have cognitive or psychiatric conditions prohibiting participation Previous participation in cognitive training program Cognitive impairment that prevents participant from answering questions in standardized assessments Cognitive deficits Cognitive, language or hearing problems No cognitive impairment Individuals that have limited cognitive function/developmental disabilities Uncontrolled congestive heart failure third-degree atrio-ventricular heart block, active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein thrombosis, resting ST displacement (> mm), uncontrolled diabetes, uncontrolled pain, cognitive impairment, history of falls due to balance impairment or lost of consciousness Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all measures independently Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional's judgement Excluded from this study will be prisoners, pregnant women, patients with a contraindication for additional lung biopsies, and patients who cannot give informed consent (language barrier, cognitive impairment, etc.) Dementia or other severe cognitive impairment causing inability to understand or consent to the procedure and study The patient must report persistent cognitive problems following the initiation of chemotherapy, defined as impairment being one or more standard deviations above normative data on our two scales of subjective cognitive dysfunction; this is defined as a total score of or higher on the Cognitive Failure Questionnaire, and a T-score of or higher on the Frontal System Behavioral Scale Questionnaire History of cognitive impairment. PHASE I: Women with capacity to participate but mild cognitive impairment (MCI) Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms -) Patients who have clinical evidence of cognitive impairment as determined by the research staff Cognitive impairment